

1 **Title:** Community Antibiotic Prescribing in Patients with COVID-19 Across Three Pandemic  
2 Waves: A Population-Based Cohort Study

3

4 **Authors:** Laura Ciaccio<sup>1</sup>, Peter T Donnan<sup>1</sup>, Benjamin J Parcell<sup>2</sup>, Charis A Marwick<sup>1</sup>

5

6 <sup>1</sup>Division of Population Health and Genomics, School of Medicine, University of Dundee,  
7 Dundee, UK.

8 <sup>2</sup>Department of Medical Microbiology, Ninewells Hospital and School of Medicine, Dundee,  
9 UK.

10

11 **Corresponding Author:**

12 Laura Ciaccio

13 University of Dundee, School of Medicine

14 Mailbox 1

15 Level 7, Corridor L

16 Ninewells Hospital

17 Dundee, DD1 9SY

18 Email: [2438067@dundee.ac.uk](mailto:2438067@dundee.ac.uk)

19 Phone: (+44) 01382383786

20

21

22

23

24

25

26 **Abstract**

27 **Background:** Reported changes in antibiotic prescribing during the COVID-19 pandemic  
28 have focused on hospital prescribing or community population trends. Community antibiotic  
29 prescribing for individuals with COVID-19 are less well described.

30 **Methods:** Data covering a complete geographic population (~800,000) were utilised. SARS-  
31 CoV-2 virus test results from February 1, 2020- March 31, 2022 were included. Anonymised  
32 data were linked to prescription data +/-28 days of the test, GP data for high-risk  
33 comorbidities, and demographic data. Multivariate binary logistic regression examined  
34 associations between patient factors and the odds of antibiotic prescription.

35 **Results:** Data included 768,206 tests for 184,954 individuals, identifying 16,240 COVID-19  
36 episodes involving 16,025 individuals. There were 3,263 antibiotic prescriptions +/-28 days  
37 for 2,385 patients. 35.6% of patients had a prescription only before the test date, 52.5% of  
38 patients after, and 11.9% before and after. Antibiotic prescribing reduced over time: 20.4% of  
39 episodes in wave one, 17.7% in wave two, and 12.0% in wave three. In multivariate logistic  
40 regression, being female (OR 1.31, 95% CI 1.19,1.45), older (OR 3.02, 95% CI 2.50, 3.68  
41 75+ vs <25 years), having a high-risk comorbidity (OR 1.45, 95% CI 1.31, 1.61), a hospital  
42 admission +/-28 days of an episode (OR 1.58, 95% CI 1.42, 1.77), and health board region  
43 (OR 1.14, 95% CI 1.03, 1.25, board B versus A) increased the odds of receiving an antibiotic.

44 **Conclusion:** Community antibiotic prescriptions in COVID-19 episodes were uncommon in  
45 this population and likelihood was associated with patient factors. The reduction over  
46 pandemic waves may represent increased knowledge regarding COVID-19 treatment and/or  
47 evolving symptomatology.

48

49

50

51 **Introduction**

52 Antibiotic surveillance and stewardship remain priorities during viral pandemics,<sup>1</sup> with the  
53 majority of antibiotics prescribed in the community.

54

55 Many studies on antibiotic use during the COVID-19 pandemic have focused on hospitalised  
56 patients. Systematic reviews report high rates of antibiotic prescriptions early in the pandemic  
57 at around 70%, despite bacterial co-infection being confirmed in less than 10% of patients.<sup>1-4</sup>

58

59 Studies of community antibiotic prescribing have largely described overall changes at the  
60 population level, particularly during the first pandemic wave.<sup>5-9</sup> NHS England reported  
61 antibiotic prescriptions decreased 15.5% from April 1 to August 31, 2020, compared to the  
62 same period in 2019 but, adjusted for the reduction in appointments, this represented an  
63 increase of 6.7%.<sup>9</sup> At the local start of the pandemic in March 2020, Scotland saw a 44%  
64 increase in community prescriptions for antibiotics commonly used to treat respiratory  
65 infections compared to 2019, but this dropped to 34% below the 2019 rate by May 2020.<sup>10</sup>

66

67 Community antibiotic prescribing for individuals with COVID-19 is less well studied.<sup>4,10,11</sup>  
68 Of two previous relevant studies, in the US<sup>11</sup> and Italy,<sup>12</sup> one used diagnostic codes rather  
69 than cases confirmed by testing and was limited to patients using one medical insurance  
70 provider.<sup>11</sup> Both examined short time intervals before and after the diagnosis (so may have  
71 under-estimated prescribing), and both covered only the first two pandemic waves.

72

73 This study aimed to examine community antibiotic prescribing rates across a complete  
74 geographic area for people with a positive COVID-19 test across three pandemic waves, and  
75 to examine health and demographic factors associated with antibiotic prescribing.

76

77

78 **Methods**

79 Anonymised data from two National Health Service Scotland (NHS) Health Boards covering  
80 approximately 20% of the Scottish population (n= 863,974) were accessed via a University of  
81 Dundee Health Informatics Centre secure remote desktop. Datasets were linked at the  
82 individual level using the Community Health Index (CHI) number, a unique identifier used to  
83 identify patients across all NHS Scotland healthcare episodes.

84

85 COVID-19 test results from 28<sup>th</sup> February 2020 (date of the first COVID-19 positive test in  
86 Scotland)<sup>13</sup> to 31<sup>st</sup> March 2022 included Polymerase Chain Reaction (PCR) test and Lateral  
87 Flow Test (LFT) results from NHS and private (with NHS contracts) laboratories and at-  
88 home tests centrally reported. Multiple tests per patient on the same day were deduplicated,  
89 and repeated positive results within 90 days were considered the same episode of COVID-19,  
90 in accordance with NHS Scotland testing guidance.<sup>14</sup>

91

92 All COVID-19 episodes were linked to community antibiotic prescriptions, demography,  
93 high-risk comorbidity/shielding, and hospital admission data. The community prescribing  
94 dataset captures dispensed prescribed items (“prescriptions”) using pharmacy claims for  
95 reimbursement. Prescriptions for all oral antibiotics in the British National Formulary  
96 (BNF), Chapter 5, subsections 5.1- Antibacterial Drugs, were included. Prescriptions from 28  
97 days prior (-28 to -1 days) to 28 days post- (0 to +28 days) positive test were included to  
98 capture pharmacy claims data batched monthly.

99

100 Demography data included calculated age, sex, health board, and Scottish Index of Multiple  
101 Deprivation quintile (SIMD5), which is based on residential postcode. Quintile 1 is the most  
102 deprived and 5 the least.

103

104 The high-risk comorbidity dataset included patients flagged in primary care records for  
105 possible shielding advice based on diagnoses and/or prescriptions. The conditions included  
106 asthma, chronic obstructive pulmonary disorder (COPD), diabetes, hypertension, ischemic  
107 heart disease, other respiratory conditions, and immunological conditions (supplementary  
108 Table S1). All patients flagged for these conditions were considered to have high-risk  
109 comorbidity.

110

111 Hospital admissions were extracted from the Scottish Morbidity Record 01 (SMR01) dataset.  
112 Admissions with a discharge date from 28 days prior to 28 days post-positive test date were  
113 included.

114

115 COVID-19 episodes were categorised into pandemic waves as previously defined for  
116 Scotland,<sup>15</sup> with the end dates of each wave extended to prevent gaps in the study period.

117 Wave 1 started 28th February 2020, wave 2 1st August 2020, and wave 3 1st May 2021.

118 Individuals could have more than one episode, in one or more waves.

119

120 Univariate and multivariate binary logistic regression analyses were used to examine  
121 associations between health and demographic factors and the likelihood of receiving a  
122 community antibiotic prescription for that COVID-19 episode. Variables included age (<25,  
123 25-44, 45-64, 65-74, 75+ years), gender, health board of residence (A vs B), high-risk  
124 comorbidity, hospital admissions +/-28 days, Scottish Index of Multiple Deprivation

125 (SIMD5) quintile, and pandemic wave. All variables were included in multivariate analysis  
126 due to social and/or clinical relevance.

127

128 All analyses used RStudio version 4.1.2.

129

130

## 131 **Results**

132 The dataset included 768,206 tests for 184,954 individuals (21.4% of the population). There

133 were 16,240 COVID-19 episodes involving 16,025 individuals. 98.7% of included

134 individuals had one episode, 1.3% had two, and 0.01% had three. The mean age at episode

135 was 51.9 years (SD 24.8), 59.4% were female, and 57.2% were in health board B (Table 1).

136 The age distribution of episodes varied across waves, with 29.0% in wave 1 involving people

137 aged 75+ years, compared to 18.2% in wave 3, and 3.0% in wave 1 aged <25 years compared

138 to 23.0% in wave 3.

139

140 The most common comorbidities were hypertension, other respiratory disorders, and asthma.

141 17.4% of those with at least one episode had one high-risk comorbidity, and 2.3% of patients

142 had 4 or more (Figure 1).

143

144 There were 3,263 antibiotic prescriptions within 28 days of 2,395 (18.1%) episodes. 853

145 (35.6%) episodes had an antibiotic prescription before the test only, 1,252 (52.3%) after only,

146 and 290 (12.1%) both before and after. The number of antibiotic prescriptions per episode

147 ranged from 1 to 8, but the majority (54.5%) had one.

148

149 Antibiotic prescribing in COVID-19 reduced over time, at 20.4% of episodes in wave one,  
150 17.7% in wave two, and 12.0% in wave three (Table 2). Amoxicillin (22.5%) and  
151 doxycycline (15.1%) were most prescribed overall, accounting for 41.1% of antibiotic  
152 prescriptions in wave 1, 34.8% in wave 2, and 37.8% in wave 3 (Table 1).

153

154 In univariate logistic regression, all variables were significantly associated with the odds of  
155 having a prescription (Table 3). In multivariate analysis, being female (OR 1.31, 95%CI 1.19  
156 to 1.45), older (OR 3.02 [2.50 to 3.68] for 75+ vs <25 years), having a high-risk comorbidity  
157 (Figure 1) (OR 1.45 [1.31 to 1.61]), having a hospital admission within 28 days of an episode  
158 (OR 1.58 [1.42 to 1.77]), and living in health board B rather than A (OR 1.14 [1.03 to 1.25])  
159 significantly increased the likelihood of receiving an antibiotic (Table 3). Having an episode  
160 in wave 2 (OR 0.86, 95% CI 0.75 to 0.99) or wave 3 (OR 0.71, 95% CI 0.62 to 0.81)  
161 significantly decreased the odds of receiving an antibiotic prescription compared to wave 1.  
162 Associations with deprivation did not show a clear trend (Table 3).

163

164

## 165 **Discussion**

### 166 **Principal findings**

167 In this large, population-based cohort study, we saw a changing patient profile for COVID-19  
168 patients over time. We found a relatively low rate of community antibiotic prescriptions for  
169 COVID-19 episodes at 14.7%, with a reduction over time, from 20.4% of episodes in wave 1  
170 to 12.0% in wave 3. We also found clear associations between individual demographic and  
171 healthcare factors and receipt of an antibiotic.

172

173 The decrease in antibiotic prescribing over time will have multiple contributing factors. Early  
174 COVID-19 treatment guidelines were modified during the pandemic as data regarding low  
175 levels of bacterial co-infection emerged.<sup>16</sup> Testing patterns also changed, and, as testing  
176 became available to the public and mandated for many sectors, misdiagnosis as bacterial  
177 infections became less likely. Vaccination roll-out, with attenuated symptom severity, may  
178 have reduced presentations with COVID-19 to community medical services, public anxiety,  
179 and clinicians' likelihood of prescribing an antibiotic. Emerging viral variants had different  
180 symptoms and/or severity,<sup>17</sup> likely affecting antibiotic prescriptions similarly to vaccination.  
181 The high proportion of amoxicillin and doxycycline prescriptions aligns with Scottish  
182 guidance for the treatment of (presumed bacterial) respiratory tract infections.<sup>18,19</sup> The  
183 proportion of prescriptions for these drugs was lowest in wave two, which may reflect the  
184 dominant variants in wave 2 (alpha and delta) having lower prevalence of respiratory  
185 symptoms.<sup>17,20</sup>  
186  
187 Older age was the strongest demographic predictor of antibiotic prescribing, likely due to  
188 higher testing rates and lower threshold for antibiotic prescriptions.<sup>21</sup> Older patients are often  
189 less likely to be asymptomatic,<sup>22</sup> and, in this study, had more hospital admissions and more  
190 comorbidity. Females were more likely to have a test, consistent with other studies,<sup>23</sup> and  
191 had more positive tests and more antibiotic prescriptions. This may reflect differences in  
192 accessing medical care, with females reportedly contacting health services more often and  
193 earlier in an illness.<sup>24</sup> The association between community prescribing and hospital  
194 admissions may reflect COVID-19 episodes requiring hospitalisation having longer  
195 symptoms and/or more concern and community healthcare contact. However, it may reflect  
196 more vulnerable individuals having more healthcare contact in general, rather than specific  
197 features of the COVID-19 episode.



198

199 Comparison with other studies

200 There are very few studies examining community antibiotic prescribing in individuals with  
201 COVID-19, with more focused on changes in total community or hospital prescribing.<sup>5-8,10</sup>  
202 Of 154 studies in a meta-analysis of antibiotic prescribing in COVID-19, 12 were mixed  
203 inpatient and outpatient settings, but none were community only.<sup>4</sup> One outpatient study  
204 completed after the previous meta-analysis examined antibiotic prescriptions for American  
205 Medicare beneficiaries with prescription drug (Part D) coverage, with an outpatient visit,  
206 including the Emergency Department, from April 2020 to April 2021 with a primary  
207 diagnosis code of COVID-19 (U071). Of >1 million encounters, around 30% of patients  
208 received an antibiotic prescription within 7 days pre- or post-visit.<sup>11</sup> This is higher than in our  
209 study (despite our longer time window pre/post-diagnosis), but the Medicare population was  
210 limited to those over 65 and to the first two pandemic waves, where we also observed higher  
211 rates. We have also been able to include all age groups, including children, rather than  
212 focusing on older individuals who were found to have greater odds of receiving an antibiotic  
213 prescription. The authors note their lack of data on underlying health conditions and hospital  
214 admissions as reported limitations,<sup>11</sup> and we found these factors were influential in  
215 prescribing.

216

217 An Italian study examined community prescriptions for 331,704 individuals with laboratory-  
218 confirmed positive COVID-19 PCR tests from March 2020 to May 2021. Prescriptions were  
219 included from 3 days pre- to 7 days post-positive test. 23% of cases received an antibiotic,  
220 with a notable increase from 18% of cases in November 2020 to 31% in March 2021.<sup>12</sup> The  
221 overall rate is higher than in our study, and the increase over time is contrary to our findings,  
222 but they did not include data from wave 3.

223

224 Studies examining trends in overall community antibiotic prescribing all report decreases  
225 across 2020. Quarterly US data reported an overall reduction, including a decrease of 44% in  
226 amoxicillin prescriptions, from calendar quarter two to quarter four.<sup>25</sup> A study from Spain  
227 reported a decrease (pooled DDD reduction) in prescribed antibiotics of 7.6% in quarter one  
228 and 36.8% in quarter two of 2020 compared to the same time in 2019.<sup>8</sup> Similarly, France and  
229 Canada reported overall reductions of 18.2% and 31.2%, respectively, in outpatient antibiotic  
230 prescriptions in 2020 compared to 2019.<sup>7,26</sup>

231

232 In hospital settings, early COVID-19 systematic reviews found that bacterial co-infections  
233 were confirmed for only around 7-8% of patients, but 70-72% received an antibiotic.<sup>1-3</sup> An  
234 April 2020 survey in Scottish hospitals found that 38.3% of patients with suspected or  
235 confirmed COVID-19 were prescribed an antibiotic.<sup>27</sup> These rates are higher than we  
236 observed, but the threshold for antibiotic prescribing will be lower in hospitalised patients,  
237 who are more unwell and higher risk, and they are from earlier in the pandemic.

238

### 239 Strengths and limitations

240 Key strengths of this study are the size of the population-level dataset and the use of  
241 administrative data, which increases generalizability and minimises the impact of any  
242 missing data. SIMD was the only variable with notable missing data (8%). These data were  
243 missing completely at random, with affected individuals evenly distributed across categories  
244 of other variables, not affecting the findings or interpretation. Another key strength is the  
245 universal use of CHI numbers (de-identified) across all NHS services, enabling multiple  
246 datasets to be linked longitudinally. The timeframe of this study allows analysis of trends  
247 over multiple pandemic waves. A limitation of this study is that data on the coded indication

248 for the antibiotic prescriptions were unavailable, so we have potentially included antibiotics  
249 prescribed for other conditions. However, primary care coding is of variable quality and  
250 utility for research,<sup>28</sup> and patients presenting with a febrile illness coded as something else  
251 but subsequently diagnosed as COVID-19 would be missed by coding. Bacteriology data  
252 were not included, and some individuals may have had bacterial secondary or co-infection  
253 with appropriate antibiotic treatment. However, most patients with presumed bacterial  
254 respiratory tract infections, including pneumonia, never have a bacteriological diagnosis,<sup>29</sup>  
255 and some bacterial pathogens can also be commensals, so bacteriology data are unlikely to  
256 facilitate evaluation of appropriateness at the population level. Data on individual COVID-19  
257 vaccination status were not available, but vaccine uptake was high in the study population  
258 ( $\geq 85\%$  of eligible population had 2+ doses).<sup>13</sup> The findings may not be generalisable to  
259 areas with different demographic characteristics (ethnicity data were unavailable), but the  
260 study regions are demographically representative of the Scottish population. Clinical  
261 outcomes of COVID-19 episodes were not included but would be prone to confounding by  
262 indication, as sicker patients would be more likely to both get an antibiotic prescription and  
263 have an adverse outcome.

264

### 265 Implications for Policy and Practice

266 The decreasing use of antibiotics found in each subsequent COVID-19 wave suggests that  
267 prescribers and the public responded to changing guidance and recommendations and became  
268 better at recognising and managing COVID-19. Reducing unnecessary antibiotic  
269 prescriptions supports antimicrobial stewardship, and the findings align with previous work  
270 indicating that vaccines to reduce symptomatic illness, including viral, can reduce antibiotic  
271 prescribing.<sup>30</sup> The difference in prescribing between health boards presents an opportunity for  
272 sharing good stewardship practice.

273

274 Although this study used rich, linked administrative data, GP consultation data are not  
275 routinely available in Scotland, and, despite the limitations, this gap should be addressed to  
276 support surveillance and research to inform practice, for example, on appropriateness of  
277 antibiotic prescriptions.

278

### 279 Implications for Future Research

280 This work highlights the need for more research on community management of individuals  
281 with COVID-19, and the drivers of potentially unnecessary antibiotic prescribing. Qualitative  
282 work with prescribers in the community could enhance understanding of practice changes  
283 over time, and with individuals who had COVID-19 could enhance understanding of changes  
284 in healthcare-seeking behaviour or access. It would also be of interest to examine whether  
285 changes in community prescribing observed in COVID-19 are replicated for other viral  
286 illnesses. These findings could inform antimicrobial stewardship and strategies, including in  
287 future viral pandemics.

288

289

### 290 Conclusions

291 Community antibiotic prescriptions in people with COVID-19 were relatively uncommon in  
292 this study population and were associated with increased age and comorbidity. There was a  
293 significant reduction over time which may represent increased knowledge and experience of  
294 COVID-19 and/or decreased symptom severity due to vaccination and changes in the  
295 dominant variants of the virus over time.

296

297

298

299 **Table 1: Study demographics**

Variable categories		Total study population	Pts with ≥1 test	Pts. with ≥1 episode	COVID Episodes		
					Wave 1*	Wave 2*	Wave 3*
Total		863974 (100%)	184953 (21.4%)	16025 (1.9%)	2430 (0.3%)	4324 (0.5%)	9434 (1.1%)
Age group	<25	200441 (23.2%)	30220 (16.3%)	2632 (16.4%)	81 (3.0%)	385 (8.9%)	2172 (23.0%)
	25-44	220996 (25.6%)	41959 (22.7%)	3888 (24.3%)	537 (22.1%)	940 (21.7%)	2464 (26.1%)
	45-64	237115 (27.4%)	52017 (28.1%)	4337 (27.1%)	849 (34.9%)	1222 (28.3%)	2313 (24.5%)
	65-74	101797 (11.8%)	23783 (12.9%)	1417 (8.8%)	258 (10.6%)	427 (9.9%)	773 (8.2%)
	75+	103625 (12.0%)	36974 (20.0%)	3751 (23.4%)	705 (29.0%)	1350 (31.2%)	1712 (18.2%)
Sex	Male	426794 (49.4%)	75605 (40.9%)	6533 (40.8%)	897 (36.9%)	1549 (35.8%)	4135 (43.8%)
	Female	437180 (50.6%)	109348 (59.1%)	9492 (59.2%)	1533 (63.1%)	2775 (64.2%)	5299 (56.2%)
Any high-risk comorbidity	No	630838 (73.0%)	113573 (61.4%)	9975 (62.2%)	1454 (59.8%)	2401 (55.5%)	6221 (65.9%)
	Yes	233136 (27.0%)	71381 (38.6%)	6050 (37.8%)	976 (40.2%)	1923 (44.5%)	3213 (34.1%)
Health board	A	404094 (46.8%)	67887 (36.7%)	6882 (42.9%)	779 (32.1%)	1667 (38.6%)	4473 (47.4%)
	B	459880 (53.2%)	117066 (63.3%)	9143 (57.1%)	1651 (67.9%)	2657 (61.4%)	4961 (52.6%)
Scottish Index of Multiple Deprivation (SIMD) quintile	1 (most deprived)	135851 (15.7%)	30411 (16.4%)	3194 (19.9%)	426 (17.5%)	888 (20.5%)	1922 (20.4%)
	2	145538 (16.8%)	31357 (17.0%)	2839 (17.7%)	374 (15.4%)	878 (20.3%)	1604 (17.0%)
	3	153304 (17.7%)	32195 (17.4%)	2808 (17.5%)	447 (18.4%)	746 (17.3%)	1650 (17.5%)
	4	203258 (23.5%)	46426 (25.1%)	3556 (22.2%)	649 (26.7%)	934 (21.6%)	2007 (21.3%)
	5 (least deprived)	152013 (17.6%)	29995 (16.2%)	2312 (14.4%)	317 (13.0%)	599 (13.9%)	1417 (15.0%)
	Missing Data	74010 (8.6%)	14569 (7.8%)	1316 (8.2%)	217 (8.9%)	279 (6.5%)	834 (8.8%)

300 \*Individuals may appear in multiple waves and may have multiple episodes in a single wave if they  
 301 occur >90 days apart  
 302  
 303

304  
305

**Table 2: Testing and Antibiotic Frequencies by UK COVID-19 Wave**

	Total tests	Mean tests per month	Total episodes	Episodes with antibiotic prescription(s) +/-28 days	Proportion of episodes with an antibiotic prescription +/-28 day
Wave 1	47606	3967	2432	496	20.4%
Wave 2	432278	48031	4330	765	17.7%
Wave 3	288232	24019	9478	1134	12.0%
Total	768206	30728	16240	2395	14.7%


306 **Wave 1:** February 28, 2020- July 31, 2020; **Wave 2:** August 1, 2020- April 30, 2021; **Wave 3:** May 1,  
307 2021-March 31, 2022 (end of study period)

308  
309  
310  
311  
312  
313

**Table 3: Associations between demographic and healthcare factors and the odds of a community antibiotic prescription for COVID-19 episodes, from binary logistic regression**


Variable	Category	Frequency	Univariate OR (95% CI)	p-value	Multivariate OR (95% CI)	p-value
Age Group	<25	2652	REF	-	-	-
	25-44	3958	1.53 (1.28, 1.84)	<0.001	1.35 (1.11, 1.64)	0.003
	45-64	4394	1.88 (1.58, 2.24)	<0.001	1.51 (1.25, 1.84)	<0.001
	65-74	1431	2.83 (2.32, 3.48)	<0.001	1.91 (1.52, 2.39)	<0.001
	75+	3805	4.89 (4.15, 5.78)	<0.001	3.02 (2.50, 3.68)	<0.001
Sex	Male	6599	REF	-	-	-
	Female	9641	1.25 (1.15, 1.37)	<0.001	1.31 (1.19, 1.45)	<0.001
High-Risk Comorbidity	No	10108	REF	-	-	-
	Yes	6132	2.34 (2.05, 2.44)	<0.001	1.45 (1.31, 1.61)	<0.001
Hospital Admission +/-28 days	No	13047	REF	-	-	-
	Yes	3193	2.28 (2.07, 2.51)	<0.001	1.58 (1.42, 1.77)	<0.001
Health Board	A	6943	REF	-	-	-
	B	9297	1.15 (1.06, 1.26)	<0.001	1.14 (1.03, 1.25)	0.01
Scottish Index of Multiple Deprivation (SIMD) quintile	1 (most deprived)	3251	REF	-	-	-
	2	2864	0.83 (0.72, 0.96)	0.01	0.81 (0.70, 0.94)	0.01
	3	2849	1.07 (0.94, 1.24)	0.29	1.00 (0.86, 1.15)	0.99
	4	3604	1.07 (0.94, 1.22)	0.31	0.88 (0.77, 1.01)	0.07
	5 (least deprived)	2341	0.93 (0.80, 1.09)	0.38	0.84 (0.72, 0.98)	0.03
COVID Wave	1	2432	REF	-	-	-
	2	4330	0.84 (0.74, 0.95)	0.005	0.86 (0.75, 0.99)	0.03
	3	9478	0.53 (0.47, 0.60)	<0.001	0.71 (0.62, 0.81)	<0.001

314 **Figure 1- Distribution of high-risk comorbidities for individuals with a COVID-19 episode and**  
 315 **proportion (%) with an antibiotic prescription in each category**



316  
 317  
 318  
 319  
 320

**Figure 2- Antibiotic prescriptions for individuals with a COVID-19 episode by high-risk comorbidity (%)**



321  
 322

\* Immunosuppression

323

324 **Transparency declaration**

325 The authors have no conflicts of interest to declare.

326 **Author contributions**

327 Concept and design: All authors. Interpretation of data: All authors. Drafting of the  
328 manuscript: LC. Manuscript revision: All authors. Statistical analysis: LC. Administrative,  
329 technical, or material support: All authors.

330 **Acknowledgements**

331 LC was funded by the Medical Research Foundation National PhD Training Programme in  
332 Antimicrobial Resistance Research (MRF-145-0004-TPG-AVISO)

333

334

335 **References**

- 336 1. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al.  
337 Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To  
338 Support COVID-19 Antimicrobial Prescribing. *Clin Infect Dis*. 2020;
- 339 2. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a  
340 systematic review and meta-analysis. *J Infection*. 2020;81(2):266–75.
- 341 3. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al.  
342 Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid  
343 review and meta-analysis. *Clin Microbiol Infect*. 2020;26(12):1622–9.
- 344 4. Langford BJ, So M, Raybardhan S, Leung V, Soucy JPR, Westwood D, et al. Antibiotic  
345 prescribing in patients with COVID-19: rapid review and meta-analysis. *Clin Microbiol*  
346 *Infect*. 2021;
- 347 5. King LM, Lovegrove MC, Shehab N, Tsay S, Budnitz DS, Geller AI, et al. Trends in US  
348 Outpatient Antibiotic Prescriptions During the Coronavirus Disease 2019 Pandemic. *Clin*  
349 *Infect Dis*. 2020;73(3):ciaa1896.
- 350 6. Buehrle DJ, Nguyen MH, Wagener MM, Clancy CJ. Impact of the Coronavirus disease  
351 2019 Pandemic on Outpatient Antibiotic Prescriptions in the United States. *Open Forum*  
352 *Infect Dis*. 2020;7(12):ofaa575-.
- 353 7. Kitano T, Brown KA, Daneman N, MacFadden DR, Langford BJ, Leung V, et al. The  
354 Impact of COVID-19 on Outpatient Antibiotic Prescriptions in Ontario, Canada; An  
355 Interrupted Time Series Analysis. *Open Forum Infect Dis*. 2021;8(11):ofab533.



- 356 8. Peñalva G, Benavente RS, Pérez-Moreno MA, Pérez-Pacheco MD, Pérez-Milena A,  
357 Murcia J, et al. Effect of the coronavirus disease 2019 pandemic on antibiotic use in primary  
358 care. *Clin Microbiol Infect.* 2021;27(7):1058–60.
- 359 9. Armitage R, Nellums LB. Antibiotic prescribing in general practice during COVID-19.  
360 *Lancet Infect Dis.* 2020;
- 361 10. Malcolm W, Seaton RA, Haddock G, Baxter L, Thirlwell S, Russell P, et al. Impact of the  
362 COVID-19 pandemic on community antibiotic prescribing in Scotland. *Jac-antimicrobial*  
363 *Resist.* 2020;2(4).
- 364 11. Tsay SV, Bartoces M, Gouin K, Kabbani S, Hicks LA. Antibiotic Prescriptions  
365 Associated With COVID-19 Outpatient Visits Among Medicare Beneficiaries, April 2020 to  
366 April 2021. *Jama.* 2022;327(20):2018–9.
- 367 12. Belleudi V, Finocchietti M, Fortinguerra F, Filippo AD, Trotta F, Davoli M, et al. Drug  
368 Prescriptions in the Outpatient Management of COVID-19: Evidence-Based  
369 Recommendations Versus Real Practice. *Front Pharmacol.* 2022;13:825479.
- 370 13. Summary -Coronavirus (COVID-19) in the UK [Internet]. 2023 [cited 2023 March 4].  
371 Available from: <https://coronavirus.data.gov.uk/>
- 372 14. COVID-19 Testing Guidance [Internet]. NHS Scotland; 2021 Jul. Available from:  
373 [https://www.southlanarkshire.gov.uk/download/downloads/id/14875/covid-](https://www.southlanarkshire.gov.uk/download/downloads/id/14875/covid-19_testing_guidance.pdf)  
374 [19\\_testing\\_guidance.pdf](https://www.southlanarkshire.gov.uk/download/downloads/id/14875/covid-19_testing_guidance.pdf)
- 375 15. Leslie K, Findlay B, Ryan T, Green LI, Harvey C, Whettlock AE, et al. Epidemiology of  
376 SARS-CoV-2 during the first three waves in Scotland: a national record linkage study. *J*  
377 *Epidemiol Commun H.* 2023;77(1):1–8.
- 378 16. Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, et al. ESCMID COVID-  
379 19 Living guidelines: drug treatment and clinical management. *Clin Microbiol Infect.*  
380 2021;28(2):222–38.
- 381 17. Looi MK. How are covid-19 symptoms changing? *BMJ* 2023;380:p3.
- 382 18. Adult Treatment of Infection Guidelines [Internet]. NHS Tayside; 2021 [cited 2022 Dec  
383 15]. Available from:  
384 [https://www.nhstaysideadtc.scot.nhs.uk/Antibiotic%20site/pdf%20docs/Antibiotic%20hospital](https://www.nhstaysideadtc.scot.nhs.uk/Antibiotic%20site/pdf%20docs/Antibiotic%20hospital%20man.pdf)  
385 [al%20man.pdf](https://www.nhstaysideadtc.scot.nhs.uk/Antibiotic%20site/pdf%20docs/Antibiotic%20hospital%20man.pdf)
- 386 19. Seaton RA, Cooper L, Gibbons CL, Malcolm W, Choo-Kang B, Griffith D, et al.  
387 Antibiotic prescribing for respiratory tract infection in patients with suspected and proven  
388 COVID-19: results from an antibiotic point prevalence survey in Scottish hospitals. *Jac-*  
389 *antimicrobial Resist.* 2021;3(2):dlab078-.
- 390 20. Buttenschøn HN, Lynggaard V, Sandbøl SG, Glassou EN, Haagerup A. Comparison of  
391 the clinical presentation across two waves of COVID-19: a retrospective cohort study. *Bmc*  
392 *Infect Dis.* 2022;22(1):423.

- 393 21. Dadras O, SeyedAlinaghi S, Karimi A, Shamsabadi A, Qaderi K, Ramezani M, et al.  
394 COVID-19 mortality and its predictors in the elderly: A systematic review. *Heal Sci*  
395 *Reports*. 2022;5(3):e657.
- 396 22. You Y, Yang X, Hung D, Yang Q, Wu T, Deng M. Asymptomatic COVID-19 infection:  
397 diagnosis, transmission, population characteristics. *Bmj Supportive Palliat Care*.  
398 2021;bmjspcare-2020-002813.
- 399 23. Stall NM, Wu W, Lapointe Shaw L, Fisman DN, Giannakeas V, Hillmer MP, et al.  
400 Sex- and Age-Specific Differences in COVID-19 Testing, Cases, and Outcomes: A  
401 Population-Wide Study in Ontario, Canada. *J Am Geriatr Soc*. 2020;68(10):2188–91.
- 402 24. Thompson AE, Anisimowicz Y, Miedema B, Hogg W, Wodchis WP, Aubrey-Bassler K.  
403 The influence of gender and other patient characteristics on health care-seeking behaviour: a  
404 QUALICOPC study. *Bmc Fam Pract*. 2016;17(1):38.
- 405 25. Buehrle DJ, Wagener MM, Nguyen MH, Clancy CJ. Trends in Outpatient Antibiotic  
406 Prescriptions in the United States During the COVID-19 Pandemic in 2020. *Jama Netw*  
407 *Open*. 2021;4(9):e2126114.
- 408 26. Bara W, Brun-Buisson C, Coignard B, Watier L. Outpatient Antibiotic Prescriptions in  
409 France: Patients and Providers Characteristics and Impact of the COVID-19 Pandemic.  
410 *Antibiotics*. 2022;11(5):643.
- 411 27. Seaton RA, Gibbons CL, Cooper L, Malcolm W, McKinney R, Dundas S, et al. Survey of  
412 antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in  
413 Scottish hospitals. *J Infection*. 2020;81(6):952–60.
- 414 28. Mills S, Brown-Kerr A, Buchanan D, Donnan PT, Smith BH. Hidden pain and palliative  
415 care in general practice out-of-hours attendances by patients with advanced cancer: an  
416 analysis of coded and uncoded free-text data. *Brit J Gen Pract*.  
417 2022;73(727):BJGP.2022.0084.
- 418 29. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Jeune IL, et al. BTS guidelines  
419 for the management of community acquired pneumonia in adults: update 2009. *Thorax*.  
420 2009;64(Suppl 3):iii1.
- 421 30. Vekemans J, Hasso-Agopsowicz M, Kang G, Hausdorff WP, Fiore A, Tayler E, et al.  
422 Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: A  
423 World Health Organization Action Framework. *Clin Infect Dis*. 2021;73(4):e1011–7.
- 424